Host Responses to Live-Attenuated ASFV (HLJ/18-7GD)

African swine fever (ASF) is a highly contagious and fatal disease caused by the African swine fever virus. Recently, the multigene family and CD2v gene-deleted ASF vaccine candidate HLJ/18-7GD was found to be safe and effective in laboratory and clinical trials. However, the immune-protective mechanisms underlying the effects of HLJ/18-7GD remain unclear. We assessed samples from pigs immunized with a single dose of 10(6) TCID50 HLJ/18-7GD. We found that pigs immunized with HLJ/18-7GD showed high levels of specific antibodies. T lymphocyte subsets (helper T cells (Th); cytotoxic T lymphocytes (CTL); double-positive T cells (DP-T cells)) were temporarily increased in peripheral blood mononuclear cells (PBMCs) after HLJ/18-7GD immunization. Once the HLJ/18-7GD-immunized pigs had been challenged with virulent HLJ/18, the percentage of Th, CTL, and DP-T cells increased significantly. PBMCs extracted from the pigs induced higher levels of CD8(+) T cells after infection with the HLJ/18 strain in vitro. The levels of GM-CSF, IFN-gamma, and TNF-alpha were upregulated at 7 days post-inoculation; this finding was contrary to the results obtained after HLJ/18 or HLJ/18 Delta CD2v infection. The immune protection from HLJ/18-7GD resulted from many synergies, which could provide a theoretical basis for HLJ/18-7GD as a safe and effective ASF vaccine.

Automated summary

A study found that the HLJ/18-7GD vaccine candidate was safe and effective in laboratory and clinical trials for African swine fever. Pigs vaccinated with HLJ/18-7GD showed high levels of specific antibodies and increased levels of T lymphocyte subsets in peripheral blood. After challenging with a virulent strain, the percentage of T lymphocyte subsets increased significantly. The study suggests that HLJ/18-7GD provides immune protection through multiple mechanisms.